Climb Bio, Inc. (CLYM)
| Market Cap | 585.28M +319.3% |
| Revenue (ttm) | n/a |
| Net Income | -57.62M |
| EPS | -0.83 |
| Shares Out | 57.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 495,679 |
| Open | 10.47 |
| Previous Close | 10.54 |
| Day's Range | 10.05 - 10.66 |
| 52-Week Range | 1.64 - 18.33 |
| Beta | -0.03 |
| Analysts | Strong Buy |
| Price Target | 27.60 (+170.85%) |
| Est. Earnings | Nov 5, 2026 |
About CLYM
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company’s lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for CLYM stock is "Strong Buy." The 12-month stock price target is $27.6, which is an increase of 170.85% from the latest price.
News
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study anti...
Climb Bio, Mabworks announce additional Phase 1 data for CLYM116/MIL116
Climb Bio (CLYM) announced additional Phase 1 data in healthy volunteers for CLYM116/MIL116, an anti-APRIL monoclonal antibody, in development for IgA nephropathy. These data were presented at the Ame...
Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026
>90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval ~70% reduction in Gd-IgA1 at 12 weeks ~33-day half-life NAVIGATE-2 Phase 2 trial enrolling, with initial data ex...
Climb Bio management to meet virtually with Piper Sandler
Virtual Meeting to be held on October 26 hosted by Piper Sandler.
Climb Bio initiated with a Buy at Deutsche Bank
Deutsche Bank initiated coverage of Climb Bio (CLYM) with a Buy rating and $28 price target Climb is a clinical-stage biotech company with two “promising” assets in development for autoimmune…
Climb Bio initiated with a Buy at Deutsche Bank
Deutsche Bank initiated coverage of Climb Bio (CLYM) with a Buy rating and $28 price target
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation
Climb Bio added to ‘Analysts Current Favorites’ at Raymond James
Raymond James added Climb Bio (CLYM) to the firm’s “Analysts Current Favorites” list while removing Tyra Biosciences (TYRA). Climb’s setup for both its lead assets – CLYM116 and budoprutug –…
Climb Bio Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Two lead assets, CLYM116 and budoprutug, are advancing in B-cell mediated diseases with strong clinical data and best-in-class profiles. CLYM116’s Q12-week dosing and sweeper mechanism offer key differentiation in IgAN, while budoprutug targets broader B-cell depletion. Multiple data readouts and pivotal trials are planned, supported by a strong financial position.
Climb Bio Transcript: Wells Fargo 21st Annual Healthcare Conference
Two antibody programs are advancing in immune-mediated diseases, with CLYM116 showing best-in-class 12-week dosing and safety in IgAN, and budoprutug demonstrating strong efficacy in pMN and ITP. Multiple pivotal trials and data readouts are planned through 2025, supported by a strong financial position.
Climb Bio price target raised to $25 from $18 at Oppenheimer
Oppenheimer raised the firm’s price target on Climb Bio (CLYM) to $25 from $18 and keeps an Outperform rating on the shares. The recent CLYM116 reveal illustrates a best-in-class clinical…
Climb Bio price target raised to $30 from $24 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Climb Bio (CLYM) to $30 from $24 and keeps a Buy rating on the shares. The CLYM116 initial Phase 1 data “display…
Climb Bio management to meet with Piper Sandler
Meeting to be held on September 11 hosted by Piper Sandler.
Climb Bio price target raised to $30 from $26 at B. Riley
B. Riley analyst Mayank Mamtani raised the firm’s price target on Climb Bio (CLYM) to $30 from $26 and keeps a Buy rating on the shares after the company shared…
Jade Biosciences price target raised to $48 from $25 at Clear Street
Clear Street raised the firm’s price target on Jade Biosciences (JBIO) to $48 from $25 and keeps a Buy rating on the shares. The firm believes Climb Bio’s (CLYM) CLYM116…
Climb Bio price target raised to $32 from $20 at BTIG
BTIG raised the firm’s price target on Climb Bio (CLYM) to $32 from $20 and keeps a Buy rating on the shares. The firm notes CLYM116’s Phase 1 results were…
Climb Bio price target raised to $25 from $21 at Baird
Baird raised the firm’s price target on Climb Bio (CLYM) to $25 from $21 and keeps an Outperform rating on the shares after the company shared Phase 1 healthy volunteer…
Climb Bio price target raised to $40 from $23 at Piper Sandler
Piper Sandler analyst Yasmeen Rahimi raised the firm’s price target on Climb Bio (CLYM) to $40 from $23 and keeps an Overweight rating on the shares after the company announced…
Climb Bio Transcript: Study result
CLYM116, a next-generation anti-APRIL antibody for IgA nephropathy, showed deep and durable APRIL suppression, robust reductions in IgA and related biomarkers, and a favorable safety profile in phase I. Modeling supports a 12-week dosing regimen, with phase II underway and phase III planned for 2027.
Climb Bio Press release: Study result
Climb Bio issued a press release on September 3, 2026, disclosing material business information to investors.
Climb Bio Slides: Study result
Climb Bio has posted slides in relation to its latest quarterly earnings report, which was published on September 3, 2026.
Climb Bio announces initial data from CLYM116 trial
Climb Bio (CLYM) announced initial data from the ongoing Phase 1 trial evaluating CLYM116, an anti-APRIL monoclonal antibody, and provided updates on its strategy for further development in IgA nephro...
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy
~29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 generally well-tolerated, with no serious adverse even...
Climb Bio to Present at Upcoming Investor Conferences
WELLESLEY HILLS, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, to...
Climb Bio price target raised to $24 from $20 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Climb Bio (CLYM) to $24 from $20 and keeps a Buy rating on the shares. The firm views the company’s competitive positioning…